AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares were down 1.6% during trading on Friday . The stock traded as low as $25.91 and last traded at $26.36, with a volume of 221,166 shares. The stock had previously closed at $26.79.

Several research analysts have recently commented on AMAG shares. Jefferies Group reiterated a “buy” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, June 2nd. Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, April 29th. Deutsche Bank AG decreased their target price on AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating for the company in a research report on Monday, May 9th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $37.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, May 5th. Finally, Raymond James Financial Inc. lowered AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 4th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $38.20.

The company has a market capitalization of $894.53 million and a price-to-earnings ratio of 86.52. The stock’s 50-day moving average price is $24.03 and its 200-day moving average price is $23.52.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 earnings per share for the quarter, missing the consensus estimate of $1.11 by $0.17. During the same period in the previous year, the company earned $1.17 earnings per share. The company earned $117.60 million during the quarter, compared to analyst estimates of $124.83 million. The business’s revenue was up 41.9% compared to the same quarter last year. Equities research analysts forecast that AMAG Pharmaceuticals Inc. will post $5.20 earnings per share for the current fiscal year.

Several institutional investors have bought and sold shares of the company. Rhumbline Advisers boosted its position in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 3,420 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock valued at $1,498,000 after buying an additional 42,208 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock valued at $1,893,000 after buying an additional 3,903 shares in the last quarter. Bank of Montreal Can boosted its position in AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock valued at $12,010,000 after buying an additional 8,435 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.